AbbVie | ABBV - Current Assets



AbbVie reported $27.68B in Current Assets for its fiscal quarter ending in March of 2025.


Current Assets Change Date
AbbVie USD 27.68B 2.09B Mar/2025
Abbott USD 24.47B 1.32B Jun/2025
ALKERMES USD 1.64B 156.24M Jun/2025
Amgen USD 26.73B 195M Jun/2025
AstraZeneca USD 28.94B 2.8B Jun/2025
Biogen USD 7.97B 341.7M Jun/2025
BioMarin Pharmaceutical USD 3.81B 337.43M Jun/2025
Bristol-Myers Squibb USD 33.22B 2.44B Jun/2025
Eisai JPY 763.15B 35.49B Jun/2025
Eli Lilly USD 49.85B 8.59B Jun/2025
Gilead Sciences USD 14.72B 2.18B Jun/2025
GlaxoSmithKline GBP 17.67B 412M Jun/2025
J&J USD 71.55B 15.66B Mar/2025
Medtronic USD 23.81B 1.3B Apr/2025
Merck USD 37.07B 1.56B Jun/2025
Neurocrine Biosciences USD 1.75B 111M Jun/2025
Novartis USD 25.94B 831M Jun/2025
Pacira USD 745.61M 14.35M Jun/2025
Perrigo USD 2.62B 82M Jun/2025
Pfizer USD 43.7B 2.16B Jun/2025
Regeneron Pharmaceuticals USD 16.86B 712.2M Jun/2025
Roche Holding CHF 40.04B 6.41B Dec/2024
Sanofi 37.02B 7B Jun/2025
UCB EUR 4.79B 1.47B Dec/2024
Ultragenyx Pharmaceutical USD 719.79M 20.63M Jun/2025
United Therapeutics USD 3.83B 112.9M Jun/2025
Vertex Pharmaceuticals USD 10.43B 419.1M Jun/2025
Zoetis USD 5.92B 46M Jun/2025